Lipid Disorders
From the Journals
Analysis supports CAC for personalizing statin use
A cross-sectional study confirms a coronary artery calcium score of 0 may obviate the need for statins in the context of risk-enhancing factors....
News
FDA to revise statin pregnancy contraindication
The changes emphasize that “statins are safe to prescribe in patients who can become pregnant” and reassure women that harm is unlikely from...
From the Journals
Cycling linked to longer life in people with type 2 diabetes
From the Journals
Statin safety, low muscle pain risk upheld in ‘reassuring’ study
The potential harms are small and the benefit-to-harm balance generally “favorable” for statin use in primary prevention of cardiovascular disease...
Conference Coverage
New agents for youth-onset type 2 diabetes ‘finally in sight’
‘A number of clinical trials of antidiabetic pharmacologic agents in diabetic youth have been completed, demonstrating safety and efficacy, and a...
From the Journals
Meta-analysis supports cardiovascular benefits of EPA
Omega-3 fatty acids improved cardiovascular outcomes, with a greater risk reduction in studies of eicosapentaenoic acid alone rather than combined...
Conference Coverage
OSA in women: Different symptoms, risks and consequences
Conference Coverage
What’s best for diabetes after metformin? GRADE outdated at outset
The GRADE trial compared four different agents as add-ons to metformin for type 2 diabetes, but the study is already outdated, said one...
Conference Coverage
EAS lipid guidance: Start high-risk patients on combo drug
Instead of starting very-high-risk patients unlikely to reach goal on a statin alone, clinicians should immediately reach for combination statin-...
Conference Coverage
AMPLITUDE-O: Efpeglenatide benefits in high-risk diabetes
In older patients with long-time type 2 diabetes and CVD or kidney disease, the investigational GLP-1 agonist efpeglenatide was safe and lowered...
Conference Coverage
Semaglutide 2.4 mg ‘likely to usher in a new era’ in obesity treatment
Clinical experience with this drug will grow rapidly over the next few years, one expert predicts, and new combination drugs are near, so...